No evidence of clinical benefits of early treatment of COVID-19 patients with hydroxychloroquine and azithromycin: Comment on "Early treatment of COVID-19 patients with hydroxychloroquine and azithromycin: A retrospective analysis of 1061 cases in Marseille, France" - Archive ouverte HAL Accéder directement au contenu
Article Dans Une Revue Travel Medicine and Infectious Disease Année : 2020

No evidence of clinical benefits of early treatment of COVID-19 patients with hydroxychloroquine and azithromycin: Comment on "Early treatment of COVID-19 patients with hydroxychloroquine and azithromycin: A retrospective analysis of 1061 cases in Marseille, France"

Dates et versions

hal-03373200 , version 1 (11-10-2021)

Identifiants

Citer

David Lebeaux, Matthieu Revest. No evidence of clinical benefits of early treatment of COVID-19 patients with hydroxychloroquine and azithromycin: Comment on "Early treatment of COVID-19 patients with hydroxychloroquine and azithromycin: A retrospective analysis of 1061 cases in Marseille, France". Travel Medicine and Infectious Disease, 2020, 36, pp.101819. ⟨10.1016/j.tmaid.2020.101819⟩. ⟨hal-03373200⟩
11 Consultations
0 Téléchargements

Altmetric

Partager

Gmail Facebook X LinkedIn More